COMPANY:

Owkin

"Owkin...and the Comprehensive Cancer Center of the Medical University of Vienna (MedUni Vienna) and University Hospital Vienna...today announced a strategic collaboration to advance cancer research and patient outcomes with the deployment of Owkin K, the first universal AI copilot for biology...As a first focus area, the collaboration will harness Owkin K’s agentic AI capabilities in the field of urologic cancers, starting with advanced bladder cancer, which is a major clinical challenge worldwide. "

"Owkin...today announced a strategic agreement with NeoGenomics...and France Tissue Bank (FTB). Owkin will leverage their respective high-quality histopathological datasets to develop the first foundation model exclusively trained on immunohistochemistry (IHC) images and made available publicly for research use."

"Owkin...and Proscia®...have announced a strategic partnership to streamline MSI testing for patients with colorectal cancer (CRC), the second most deadly cancer worldwide. As a first step in the collaboration, the companies will integrate Owkin’s MSIntuit CRC v2 with Proscia’s Concentriq software platform for studying its impact, and make it available as part of Proscia’s precision medicine AI portfolio to enable laboratories to keep pace with demand for MSI screening."

"Owkin...has announced MSIntuit CRC v21, a next-generation AI solution. Aimed at transforming the detection and treatment of colorectal cancer (CRC), MSIntuit CRC v2 will initially launch as an RUO version in the US on Roche’s navify Digital Pathology enterprise software. MSIntuit CRC v2 builds upon the success of the CE-IVD-certified MSIntuit CRC, integrating cutting-edge machine learning models developed by Owkin with Roche's unparalleled expertise in oncology diagnostics....This latest version features a new architecture with advanced machine learning models significantly enhancing model performance."

"Owkin...is pleased to announce a new partnership with AstraZeneca...to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides. As part of Owkin’s ongoing collaboration with Gustave Roussy and The Centre Léon Bérard through PortrAIt, a French consortium to accelerate precision medicine through AI-enabled digital pathology, this tool aims to significantly accelerate and expand access to gBRCA testing that too many patients may not be considered for."

"Owkin said...that it has expanded its artificial intelligence-enabled precision medicine platform to nine centers in Germany, Austria, and Switzerland...The research and drug-discovery partnerships will focus on prostate cancer, muscle-invasive bladder cancer (MIBC), and cardiovascular disease. For its part, Owkin will bring its BiomarkerPlus outcome prediction platform; its TargetMatch target discovery platform; and its TrialPlus clinical trial optimization platform."

"Aster Insights...and Owkin...are excited to announce a collaboration to accelerate key transatlantic research in breast cancer diagnostics...Aster Insights and Owkin are in the process of entering into a multi-year relationship with breast cancer designated as the first area of research focus."

"Owkin and University Hospitals Birmingham NHS Foundation Trust (UHB) announced...a new five year research partnership to use artificial intelligence (AI) to accelerate the screening and diagnosis of a range of diseases, starting with colorectal cancer...The first research project in this collaboration aims to evaluate the performance of Owkin’s MSIntuit CRC solution in the United Kingdom across UHB’s cohort of 830 patients with primary colorectal adenocarcinoma."

"...Owkin...announced it is working with Amazon Web Services (AWS) to transform drug discovery, de-risk and accelerate clinical trials, and develop AI diagnostics. Owkin will leverage AWS’s proven global infrastructure and secure, extensive and reliable cloud platform to enhance data operations, optimize for operational excellence, and drive forward research in precision medicine."

"Owkin and the team at Sorbonne University and Assistance Publique - Hôpitaux de Paris (AP-HP) are looking to change that by learning more about cancer patients, through artificial intelligence...The teams will focus initially on pancreatic cancer, a cancer that is frequently diagnosed at an advanced stage, thereby reducing the chances of recovery, since symptoms typically only appear after it has spread to other organs."

"Evotec SE...and Owkin...announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation ('I&I')...The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and develop new therapeutics. Harmonising Owkin's cutting-edge target discovery engine with Evotec's end-to-end shared R&D platforms and disease biology expertise will accelerate Owkin's novel programmes from the discovery phase to the clinic."

"Owkin...and Cerba Path...announced a new partnership. The two companies will work together to integrate Owkin’s cutting-edge AI-driven diagnostics into Cerba Path’s routine digital workflows and further validate AI-based tools for precision medicine...This partnership between Owkin and Cerba Path will have Cerba Path deploy Owkin’s technology to enhance pathologists’ and clinicians’ ability to accelerate precision medicine and deliver better patient care. Owkin’s AI diagnostics will benefit from Cerba Path’s fully digitized workflow and be able to reach a broader audience of pathologists who can access the Cerba Path platform remotely from any location in France."